Fig. 2

Compound 1 administration in vivo inhibits SIRT6 enzymatic activity and reduces cell number in spleen and lymph node and lymphocyte infiltration in spinal cord. Mice were treated (or not) with 1 (administered twice/day), following the preventive protocol (see the “Materials and methods” section). a At 7 dpi, splenocytes were collected and homogenized, and Western blot analyses were performed to evaluate the level of acetylated H3K9 (H3K9-Ac). A representative Western blot analysis is shown, together with the normalized quantification of the band intensity (n = 6). b, c At the indicated time points, the total cell number in spleen (b) and in lymph nodes (c) was evaluated. Data are expressed as mean ± SD from 6 animals. d At 15–17 dpi (i.e., 4 days post onset in vehicle-treated mice), spinal cords were collected from 1-treated and vehicle-treated animals. Immunofluorescence analyses were performed, upon staining of the infiltrating lymphocytes with an anti-CD4 antibody. Representative images are shown, together with the quantification of at least 10 different images, from 3 animals for each conditions. *p < 0.05, **p < 0.01 compared to the relative control. Data were analyzed by t test